Annovis (NYSE: ANVS) announced publication of a historical review of its lead candidate buntanetap in The Scientist on March 31, 2026. The article traces buntanetap's discovery, chemical refinement and clinical progress, and places its development in scientific and historical context.
Clinical status: pivotal Phase 3 in early AD (NCT06709014) is 70% enrolled; PD open‑label extension (NCT07284784) is 20% enrolled.
Loading...
Loading translation...
Positive
Phase 3 AD trial at 70% patient enrollment
Historical review in The Scientist increases scientific visibility
Negative
PD extension enrollment at only 20%, suggesting slower recruitment
News Market Reaction – ANVS
+10.95%
11 alerts
+10.95%Session close to close
+7.6%Peak Tracked
-4.8%Trough Tracked
$64.08MMarket Cap
1.0xRel. Volume
In the Mar 31 session, ANVS gained 10.95%, reflecting a significant positive market reaction.
Argus tracked a peak move of +7.6% during that session.
Argus tracked a trough of -4.8% from its starting point during tracking.
Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
The stock surged +10.9% in the session following this news. A strong positive reaction aligns with a...
Analysis
The stock surged +10.9% in the session following this news. A strong positive reaction aligns with a narrative of steady clinical execution: the article highlights buntanetap’s long development arc and notes that the pivotal AD Phase 3 has 70% enrollment with the PD open-label extension at 20%. Past buntanetap updates have often coincided with constructive moves. However, the stock trades well below its $5.50 52-week high, and prior volatility means enthusiasm could fade if clinical timelines or data catalysts disappoint.
Key Figures
AD Phase:Phase 3AD enrollment:70% patients enrolledPD OLE enrollment:20% patients enrolled+5 more
8 metrics
AD PhasePhase 3Pivotal study of buntanetap in early Alzheimer’s disease
AD enrollment70% patients enrolledPivotal Phase 3 early AD trial (NCT06709014)
PD OLE enrollment20% patients enrolledOpen-label extension PD study (NCT07284784)
Historical span19th century originsArticle traces buntanetap’s development from original discovery
Current price$2.01Pre-news close for ANVS
52-week range$1.11–$5.5052-week low and high before this news
Market cap$57,561,182Equity value prior to article publication
Announced 36‑month open-label extension for PD to support NDA readiness.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamentally positive updates on buntanetap have more often seen supportive price reactions, though there are instances where favorable or neutral news coincided with flat-to-negative moves.
Recent Company History
Over the past several months, Annovis has focused on advancing buntanetap through later-stage development. Key milestones included DSMB approval to continue the pivotal Alzheimer’s Phase 3 trial (Feb 12, 2026), two scientific presentations at AD/PD 2026, and a partnership to deploy an FDA-cleared AI digital biomarker platform in a long-term Parkinson’s study. Fiscal 2025 results highlighted initiation of the pivotal AD trial and an open-label PD extension. Today’s publication in The Scientist reinforces buntanetap’s scientific and developmental narrative alongside this clinical and regulatory progress.
Key Terms
phase 3, open-label extension, mechanism of action, clinical trials, +4 more
8 terms
phase 3medical
"Buntanetap is currently being evaluated in a pivotal Phase 3 study in early AD"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
open-label extensionmedical
"and in an open-label extension study in PD (NCT07284784)"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
mechanism of actionmedical
"the identification of its mechanism of action to the search for the correct chemical form"
Mechanism of action describes how a drug, therapy, or medical product produces its effect in the body—the specific steps, targets, and biological processes it engages, like a key fitting into a lock to open a door. Investors care because a clear, well-understood mechanism reduces scientific uncertainty, supports regulatory approval and market confidence, and helps predict safety, effectiveness and additional uses, all of which influence a product’s commercial potential and a company’s valuation.
clinical trialsmedical
"its progression through clinical trials. It also illuminates the complex journey"
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.
neurodegenerative diseasesmedical
"for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD)"
Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.
nct06709014medical
"pivotal Phase 3 study in early AD (NCT06709014), with 70% patients enrolled"
NCT06709014 is a unique identifier assigned to a specific clinical study registered on ClinicalTrials.gov, a public database of medical trials. For investors, this ID acts like a tracking number that lets you find detailed information about the study’s purpose, design, progress and results—similar to checking a product’s serial number—so you can assess how trial outcomes might affect a company’s drug prospects, regulatory timeline and potential market value.
nct07284784medical
"open-label extension study in PD (NCT07284784), with 20% patients enrolled"
NCT07284784 is a unique identifier assigned by ClinicalTrials.gov to a specific registered clinical trial; it functions like a catalog number that lets anyone find the trial’s protocol, enrollment criteria, status, and results in a public database. Investors use these identifiers as a quick link to verify where a drug or medical device stands in testing — akin to checking a shipment tracking number — because trial design, progress, and outcomes can materially affect a company’s future value.
regulatory milestonesregulatory
"as we approach important clinical and regulatory milestones."
Regulatory milestones are the key official steps a company must reach with government agencies—such as filings, approvals, clearances or formal reviews—before a product or business activity can move forward. For investors they matter because hitting or missing these milestones can change a company’s ability to sell products, unlock revenue, reduce legal and development risk, or trigger payments, much like a traffic light or checkpoint that determines whether a project can continue on schedule.
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer’s Disease Drug”, examining the history of discovery and development of buntanetap, the Company's lead drug candidate.
As Annovis advances its clinical pipeline with both AD and PD trials actively enrolling patients, this historical review offers important context for understanding buntanetap's scientific journey and its significance in the neurodegenerative disease space. The article traces the compound's development from its 19th-century origins and the identification of its mechanism of action to the search for the correct chemical form and its progression through clinical trials. It also illuminates the complex journey of drug development shaped by scientific rigor, cultural context, and corporate evolution, providing an accessible yet scientifically grounded account of the discovery, optimization, and refinement that have brought buntanetap to its current stage of development. Buntanetap is currently being evaluated in a pivotal Phase 3 study in early AD (NCT06709014), with 70% patients enrolled, and in an open-label extension study in PD (NCT07284784), with 20% patients enrolled.
"Buntanetap is the product of more than a century and a half of pharmacological refinement and clinical learning," said Alexander Morin, Ph.D., Director of Strategic Communications at Annovis. "This article is an opportunity to share that story in accessible language, tracing the key moments that have brought buntanetap to where it stands today. It also reflects Annovis' commitment to scientific transparency and education as we approach important clinical and regulatory milestones."
The Scientist is a leading magazine serving life science professionals, researchers, and clinicians with in-depth coverage of the latest discoveries, technologies, and perspectives shaping biomedical research. With rigorous editorial standards and a highly engaged scientific readership, The Scientist provides a trusted platform for communicating advances in biology, medicine, and drug development.
About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com
Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com
FAQ
What is buntanetap and why does Annovis (ANVS) highlight it on March 31, 2026?
Buntanetap is an investigational oral therapy for Alzheimer’s and Parkinson’s disease. According to the company, the article summarizes its 19th‑century origins, mechanism optimization, and clinical development through current Phase 3 testing.
How far along is the ANVS Phase 3 study in early Alzheimer’s disease (NCT06709014)?
The Phase 3 early AD study is currently 70% enrolled. According to the company, this reflects substantial progress toward completing patient enrollment for the pivotal trial.
What does 20% enrollment in the PD open‑label extension (NCT07284784) mean for ANVS timelines?
Twenty percent enrollment indicates early-stage recruitment for the PD extension and potential timeline risk. According to the company, recruitment continues as patients complete the primary trials and transition to the extension.
How might publication in The Scientist affect Annovis (ANVS) investor perception?
Publication can raise scientific credibility and visibility among researchers and clinicians. According to the company, the review aims to contextualize buntanetap's development and support transparency ahead of clinical and regulatory milestones.
Where can investors read the buntanetap historical review mentioned by ANVS on March 31, 2026?
The article is published in The Scientist and is accessible online. According to the company, readers can find the full historical review on The Scientist's official website for detailed context.
Does the March 31, 2026 announcement report any regulatory approvals for buntanetap?
No, the announcement does not report regulatory approvals or trial results. According to the company, the piece is a historical review and reiterates ongoing Phase 3 and extension trial enrollment updates.
